Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy

Urology

Volumn 64, Issue 2, 2004, Pages 335-340

  Conde, Francisco A ^a   Sarna, Linda ^a   Oka, Roberta K ^a   Vredevoe, Donna L ^a   Rettig, Matthew B ^a,b   Aronson, William J ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d 11301 Wilshire Blvd Bldg 500 R ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; HEALTH STATUS; HIP; HUMAN; LIFESTYLE; LUMBAR VERTEBRA; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; ALCOHOL DRINKING; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BODY MASS INDEX; BONE DENSITY; BONE DISEASES, METABOLIC; CLINICAL TRIALS; COHORT STUDIES; COMBINED MODALITY THERAPY; COMORBIDITY; DENSITOMETRY, X-RAY; FEMUR NECK; HUMANS; LIFE STYLE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OBESITY; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SMOKING; SOCIOECONOMIC FACTORS; THINNESS; TUMOR MARKERS, BIOLOGICAL;

EID: 4143147643     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.03.036     Document Type: Article

References (27)

1. Daniell H. Osteoporosis after orchiectomy for prostate cancer. J Urol. 157:1997;439-444
2. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 162:2000;181-186
3. Eriksson S., Eriksson A., Stege R., et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 57:1995;97-99
4. Hatano T., Oishi Y., Furuta A., et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 86:2000;449-452
5. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 167:2002;2361-2367
6. Townsend M.F., Sanders W.H., Northway R.O., et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 79:1997;545-550
7. Wei J.T., Gross M., Jaffe C.A., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 54:1999;607-611
8. Diamond T., Campbell J., Bryant C., et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate cancer. Cancer. 83:1998;1561-1566
9. Maillefert J.F., Sibilia J., Michel F., et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 161:1999;1219-1222
10. Ybarra J., Ade R., Romeo J.H. Osteoporosis in men a review. Nurs Clin North Am. 31:1996;805-813
11. Orwoll E.S. Osteoporosis in men. Endocrinol Metab Clin North Am. 27:1998;349-367
12. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies development and validation. J Chronic Dis. 40:1987;373-383
13. Katz J.N., Chang L.C., Sangha O., et al. Can morbidity be measured by questionnaire rather than medical record review? Med Care. 34:1996;73-84
14. Washburn R.A., Smith K.W., Jette A.M., et al. The physical activity scale for the elderly (PASE) development and evaluation. J Clin Epidemiol. 46:1993;153-162
15. Washburn R.A., McAuley E., Katula J., et al. The physical activity scale for the elderly (PASE) evidence for validity. J Clin Epidemiol. 52:1999;643-651
16. Blake G.M., Fogelman I. Principles of bone densitometry. Bilezikian J.P., Raisz L.G., Rodan G.A. Principles of Bone Biology. 1996;1313-1332 Academic Press, San Diego
17. Smith MR: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60(3 suppl 1): 79-85, 2002
18. Orwoll E.S., Oviatt S.K., McClung M.R., et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med. 112:1990;29-34
19. Stetler-Stevenson W.B., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 9:1993;541-573
20. Cottam D.W., Rees R.C. Regulation of matrix metalloproteinases their role in tumor invasion and metastasis. Int J Oncol. 2:1993;861-872
21. Ershler W.B., Harman S.M., Keller E.T. Immunologic aspects of osteoporosis. Dev Com Immunol. 21:1997;487-499
22. Ross P.D. Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am. 27:1998;289-301
23. Burger H., de Laet C.E., van Daele P.L., et al. Risk factors for increased bone loss in an elderly population the Rotterdam study. Am J Epidemiol. 147:1998;871-879
24. Nguyen T.V., Eisman J.A., Kelly P.J., et al. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 144:1996;255-263
25. Melton L.J. III, Atkinson E.J., O'Fallon W.M., et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 8:1993;1227-1233
26. Higano CS: Management of bone loss in men with prostate cancer. J Urol 170:S59-S63, 2003
27. Conde FA, and Aronson WJ: Risk factors for male osteoporosis. Urol Oncol 5:380-383, 2004